share_log

Piper Sandler Maintains Overweight on Cue Biopharma, Lowers Price Target to $3

Benzinga ·  Jul 26 21:53  · Ratings

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and lowers the price target from $8 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment